Intelligence · Clinical pipeline
Oncology · Phase I
Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase I programs: NovaPharmaNews indexes 1,319 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- Chinese Academy of 70 programs
- First People's Hospital 62 programs
- Takeda 49 programs
- United Therapeutics Europe 41 programs
- BEONE MEDICINES AUS 40 programs
- Regeneron UK 34 programs
- Anaxis Pharma 31 programs
- Chongqing Precision Biotech 27 programs
- Janssen-Cilag International N.V 27 programs
- Novartis India 27 programs
- Boehringer Ingelheim 24 programs
- BRIGHT MINDS BIOSCIENCES 23 programs
Pipeline programs
-
OMTX705-001
Lacuna Pharma Pty Ltd
Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).
1 trial -
OMTX705-006 Phase 1b
Lacuna Pharma Pty Ltd
Advanced/Metastatic Pancreatic Adenocarcinoma
1 trial -
ONC206
Jazz Pharmaceuticals Ireland Limited
Central Nervous System Neoplasms
1 trial -
ONC206 Powder
AXIM BIOTECHNOLOGIES, INC.
Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors
1 trial -
ONO-4578
Ono Pharmaceutical Co.,
Metastatic Pancreatic Cancer
1 trial -
OP-3136
Olema Pharmaceuticals
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
1 trial -
OPB-31121
Otsuka Beijing Research Institute
Non-Hodgkin's Lymphoma(NHL)
1 trial -
OPB-51602
Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma
1 trial -
ORIC-101
Topiloric/Uriadec
Solid Tumor
1 trial -
ORIC-101
Topiloric/Uriadec
Prostatic Neoplasms
1 trial -
ORIC-114 Dose 1 + amivantamab
Topiloric/Uriadec
Solid Tumors
1 trial -
ORIC-944
Topiloric/Uriadec
Metastatic Prostate Cancer
1 trial -
Odronextamab
Regeneron UK Limited
B-cell Non-Hodgkins Lymphoma (B-NHL)
1 trial -
Odronextamab multiple dose levels
Regeneron UK Limited
Non-Hodgkin Lymphoma
1 trial -
Olaparib tablets, 150 mg
Sandoz Pty Ltd
Ovarian Cancer
1 trial -
Olutasidenib Investigational Agent Administration
RIGEL PHARMACEUTICALS INC
Acute Myeloid Leukemia
1 trial -
Omacetaxine
Teva Pharma GmbH
Hematologic Tumors
1 trial -
Onartuzumab
Hoffmann-La Roche
Carcinoma, Hepatocellular
1 trial -
Oncolytic Virus SDJ001
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Malignant Tumor
1 trial -
Optical PD-L1 imaging using Quantitative Fluo... for Esophageal cancer
Disc Medicine
Esophageal cancer
1 trial -
Osimertinib
PUMA BIOTECHNOLOGY, INC.
Lung Cancer Metastatic
1 trial -
PAN-301-1
Sensei Biotherapeutics
Prostate Cancer
1 trial -
PARP inhibitor BMN-673
BioMarin Pharmaceutical Australia Pty Ltd
Metastatic Cancer
1 trial -
PB-2018-V12
Chongqing Precision Biotech Co., Ltd
Non-small Cell Lung Cancer
1 trial -
PCS6422 and capecitabine
Processa Pharmaceuticals
Advanced Cancer
1 trial -
PD-L1/IDO Peptide Vaccine
IO Biotech
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
1 trial -
PDR001
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
1 trial -
PDR001
Novartis Pharmaceuticals
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
1 trial -
PEGPH20
HALOZYME THERAPEUTICS, INC.
Cholangiocarcinoma Non-resectable
1 trial -
PEGPH20
HALOZYME THERAPEUTICS, INC.
Solid Tumor
2 trials -
PEGylated recombinant human hyaluronidase PH20
HALOZYME THERAPEUTICS, INC.
Non-small Cell Lung Cancer
1 trial -
PERSEVERANCE EU
CERO THERAPEUTICS HOLDINGS, INC.
Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory
1 trial -
PH-762
Phio Pharmaceuticals
Squamous Cell Carcinoma of the Skin
1 trial -
PH-ACP3GA-01/24
Philogen S.p.A.
Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
PH-ACP3GA-03/25
Philogen S.p.A.
Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
PH-CAIXGA-02/24
Philogen S.p.A.
Patients with suspected clear cell renal cell carcinoma (ccRCC)
1 trial -
PH-FAPLU-02-23
Philogen S.p.A.
Patients with advanced/metastatic FAP-positive tumors
1 trial -
PH-L19IL2CORK-01/25
Philogen S.p.A.
Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma
1 trial -
PIC1 Injection
Chongqing Precision Biotech Co., Ltd
Non-Hodgkin Lymphoma
1 trial -
PIVEKIMAB SUNIRINE
AbbVie Deutschland GmbH & Co. KG
Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia
1 trial -
PLATFORMPACAN1001
Janssen-Cilag International N.V.
Non-Hodgkin lymphoma and chronic lymphocytic leukemia
1 trial -
PLN-101095
PLIANT THERAPEUTICS, INC.
Advanced or Metastatic Solid Tumor
1 trial -
PM14-A-003-20
Lacuna Pharma Pty Ltd
Advanced solid tumors
1 trial -
PONAT-14-25
Lacuna Pharma Pty Ltd
chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia
1 trial -
PRG2302
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia
1 trial -
PRIMROSE D9970C00001
AstraZeneca AB
Advanced/metastatic solid tumors that are MTAP deficient.
1 trial -
PRT1419
Prelude Therapeutics Inc
Acute Myeloid Leukemia
1 trial -
PRT1419
Prelude Therapeutics Inc
Sarcoma
1 trial
Frequently asked questions
How many oncology Phase I programs exist?
1,319 programs match both the therapeutic area and stage filters in our published index.